PROGRAMME
Two days of clinically
relevant science
Explore the full scientific programme – from clinical implementation and disease-specific evidence to emerging applications of liquid biopsy and ctDNA.
10–11 NOVEMBER 2026 · UPPSALA, SWEDEN
Programme updated 2 September · Subject to change
DAY 1 · TUESDAY, 10 NOVEMBER
Joint conference day with the European Liquid Biopsy Society
REGISTRATION
Registration open 12.00-15.00
10.00–13.00 · ELBS OPEN SCIENTIFIC SESSION
13.00–14.00 · LUNCH
14.00–15.45 · SESSION 1
WELCOME
Richard Rosenqvist Brandell, MD, PhD Professor of Clinical Genetics and Senior Physician, Karolinska Institutet and Karolinska University Hospital, Sweden. Director of Genomic Medicine Sweden.
CLINICAL IMPLEMENTATION: CHALLENGES FOR ctDNA TESTS
Klaus Pantel, MD, PhD Professor of Medicine and Director, Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany. Founder and Chairman of the European Liquid Biopsy Society.
CIRCULATING TUMOR DNA IN PROSTATE CANCER: FROM RETROSPECTIVE RESEARCH AND THE PROSPECTIVE PROBIO TRIAL TO CLINICAL ROUTINE IMPLEMENTATION
Johan Lindberg, PhD Principal Researcher and Associate Professor (Docent), Karolinska Institutet, Sweden.
OVARIAN CANCER & CTDNA BIOINFORMATICS
Jaana Oikkonen, PhD Postdoctoral Researcher, University of Helsinki, Finland.
ABSTRACT PRESENTATION
GOLD SPONSOR PRESENTATION · NATERA
SIGNATERA MRD ACROSS TUMOR TYPES: EVIDENCE, CLINICAL APPLICATIONS AND EVOLVING ONCOLOGY PRACTICE
Enrico de Toni International Senior Medical Director, Oncology, at Natera and Professor of Medicine at the University of Munich.
15.45–16.15 · COFFEE AND POSTER MINGLE
16.15–18.00 · SESSION 2
ABSTRACT PRESENTATION
ctDNA/RNA MONITORING IN SARCOMAS AND BEYOND
Anders Ståhlberg, PhD Professor of Molecular Medicine, University of Gothenburg, Sweden. Expert in liquid biopsy technologies, circulating tumor DNA and single-cell analysis.
cfDNA IN ENDOMETRIAL CANCER
Kristina Lindemann, MD, PhD Professor of Gynecologic Oncology and Senior Consultant, University of Oslo and Oslo University Hospital, Norway.
CELL-FREE HPV DNA AS A BIOMARKER IN CERVICAL CANCER
Emma Tham MD, PhD Professor of Clinical Genetics and Senior Consultant Clinical Geneticist, Karolinska Institutet and Karolinska University Hospital, Sweden.
PANEL DISCUSSION
LIQUID BIOPSY – WE CAN MEASURE, BUT HOW LOW DO WE NEED TO GO? SPECIFICITY AND SENSITIVITY
Johan Lindberg, Jaana Oikkonen, Anders Ståhlberg, Kristina Lindemann, Emma Tham
SUMMARY
19.00 · DINNER AT MUSEUM GUSTAVIANUM
DAY 2 · WEDNESDAY, 11 NOVEMBER
REGISTRATION
Registration open 08.30-10.00
09.00-10.30 · SESSION 3
START UP: REVIEW OF YESTERDAY AND TODAY’S FOCUS
CIRCULATING TUMOR DNA FOR DIAGNOSIS AND MONITORING IN B-CELL LYMPHOMAS
Zahra Haider, PhD Researcher, Karolinska Institutet, Sweden.
ctDNA IN LYMPHOMA
Sirpa Leppä, MD, PhD Professor of Oncology and Senior Consultant Hematologist, University of Helsinki and Helsinki University Hospital, Finland.
LIQUID BIOPSIES FOR TREATMENT RESPONSE IN CHILDHOOD CANCER
Martin Dalin MD, PhD Associate Professor and Research Group Leader, University of Gothenburg and Sahlgrenska University Hospital, Sweden.
ABSTRACT PRESENTATION
10.30-11.00 · COFFEE AND POSTER MINGLE
11.00-12.30 · SESSION 4
FROM RESECTION TO ADJUVANT THERAPY AND RECURRENCE PREDICTION: THE ROLE OF ctDNA IN POST-SURGERY CRC MANAGEMENT
Claus Lindbjerg Andersen, PhD Professor of Translational Cancer Research, Aarhus University, Denmark.
PREDICTING CANCER ONSET IN LYNCH SYNDROME BY LIQUID BIOPSIES (PREDI-LYNCH): STUDY PROTOCOL FOR AN INTERNATIONAL, MULTICENTRE, RANDOMISED CONTROLLED TRIAL
Toni Seppälä, MD, PhD Associate Professor and Colorectal Surgeon, University of Helsinki and Helsinki University Hospital, Finland.
ctDNA IN CRC
Cecilia Merk, MD PhD Student, Department of Molecular Medicine and Surgery, Karolinska Institutet, Sweden.
ctDNA IN THE CLINICAL MANAGEMENT OF MUSCLE INVASIVE BLADDER CANCER
Lars Dyrskjøt, Msc, PhD Professor of Molecular Medicine, Aarhus University and Aarhus University Hospital, Denmark.
12.30–13.30 · LUNCH
13.30-15.00 · SESSION 5
CTDNA TESTING IN CLINICAL PRACTICE IN FRANCE AND THE EXPERIENCE WITH A CGP IN GUSTAVE ROUSSY
Etiènne Rouleau, MD, PhD Head of the Genetics Unit, Gustave Roussy Cancer Center, France.
FROM RESEARCH TO PRACTICE; PLASMA 1ST DIAGNOSIS OF LUNG CANCER
Alastair Greystoke, MBBS, PhD Professor of Medical Oncology and Honorary Consultant Medical Oncologist, Newcastle University and Newcastle Hospitals NHS Foundation Trust, UK.
ctDNA IN LUNG CANCER
Maria Planck, MD, PhD Associate Professor and Senior Consultant, Lund University and Skåne University Hospital, Sweden.
ABSTRACT PRESENTATION
15.00-15.30 · COFFEE AND POSTER MINGLE
15.30-17.00 · SESSION 6
BEYOND DETECTION: WHEN SHOULD CTDNA DRIVE TREATMENT IN BREAST CANCER?
Isaac Garcia-Murillas PhD Group Leader, Breast Cancer Liquid Biopsy Laboratory, The Institute of Cancer Research, London, UK.
ctDNA IN BREAST CANCER (NORDIC)
Lao Saal, MD, PhD Professor of Oncology, Lund University, Sweden. Senior Consultant and translational cancer genomics researcher.
ABSTRACT PRESENTATION
PANEL DISCUSSION
LIQUID BIOPSY – CAN WE ACT ON IT AND HOW DO WE IMPLEMENT?
Sirpa Leppä, Claus Lindbjerg, Alastair Greystoke, Isaac Garcia-Murillas